June 2026 Quarterly Activities Report & Appendix 4C

• Positive interim analysis for Phase III insomnia program
• Independent DMB recommends continuing the trial without increasing sample size
• No serious adverse events reported in the first 244 participants
• Approximately $1.9 million raised through exercised listed options
• $1.98 million received from R&D Tax Incentive Scheme

Avecho Biotechnology Limited (ASX: AVE) has reported positive interim analysis results for its Phase III insomnia trial, which has been recommended to continue by an independent Data Monitoring Board (DMB). The DMB's unanimous recommendation to proceed with the trial at the original sample size of 519 participants significantly de-risks the program. Importantly, no serious adverse events were identified among the first 244 participants receiving 75mg CBD, 150mg CBD, or placebo. The company also raised approximately $1.9 million through the exercise of listed options and received $1.98 million under the Australian Government's Research and Development Tax Incentive Scheme, which was used to repay advances from Endpoints Capital. As of 30 June 2026, Avecho held a cash position of $6.6 million.

Avecho Biotechnology's Phase III insomnia trial continues as planned, with no increase in sample size required.

Avecho Biotechnology plans to engage with international regulatory authorities to determine potential development and registration pathways in additional markets.